Long-term study of liver side effects from Turalio
Part of Bones, joints & muscles, Cancer clinical trials.
This study follows adults taking Turalio (pexidartinib) to understand how often it causes liver problems and what those liver changes look like over time. It may help improve monitoring and safety for people who develop liver test abnormalities during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 years or older) with symptomatic TGCT that causes major problems and can’t be fixed with surgery
- You must have had liver test changes that were linked to Turalio (pexidartinib) exposure
- Your liver test pattern must match one of these: AST/ALT >3× and bilirubin >2×, or bilirubin alone >2× (not from Gilbert’s syndrome)
- Another acceptable pattern is AST or ALT alone >10×, or ALP >2× with GGT >2×
- You must agree to study procedures and long-term safety follow-up, and allow use of related Turalio risk-program data
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (DCC-3014) for people with TGCT, a non-cancerous joint tumor. The drug may help reduce pain and improve joint movement without the risks of surgery.
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
Hear when a new Hepatotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.